DK1280486T3 - Minimering af bivirkning forbundet med oxybutinin-terapi - Google Patents

Minimering af bivirkning forbundet med oxybutinin-terapi

Info

Publication number
DK1280486T3
DK1280486T3 DK01927318.4T DK01927318T DK1280486T3 DK 1280486 T3 DK1280486 T3 DK 1280486T3 DK 01927318 T DK01927318 T DK 01927318T DK 1280486 T3 DK1280486 T3 DK 1280486T3
Authority
DK
Denmark
Prior art keywords
therapy
oxybutinin
side effect
oxybutynin
effect associated
Prior art date
Application number
DK01927318.4T
Other languages
Danish (da)
English (en)
Inventor
Steven W Sanders
Charles D Ebert
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24234699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1280486(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1280486T3 publication Critical patent/DK1280486T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01927318.4T 2000-04-26 2001-04-24 Minimering af bivirkning forbundet med oxybutinin-terapi DK1280486T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55971100A 2000-04-26 2000-04-26
PCT/US2001/013135 WO2001080796A1 (en) 2000-04-26 2001-04-24 Minimizing adverse experience associated with oxybutynin therapy

Publications (1)

Publication Number Publication Date
DK1280486T3 true DK1280486T3 (da) 2011-02-14

Family

ID=24234699

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01927318.4T DK1280486T3 (da) 2000-04-26 2001-04-24 Minimering af bivirkning forbundet med oxybutinin-terapi

Country Status (15)

Country Link
US (6) US6743441B2 (enExample)
EP (3) EP1280486B1 (enExample)
JP (3) JP2003531157A (enExample)
CN (4) CN101843601A (enExample)
AT (1) ATE488233T1 (enExample)
AU (2) AU2001253782B2 (enExample)
BR (1) BR0110381A (enExample)
CA (1) CA2406064C (enExample)
CY (1) CY1111498T1 (enExample)
DE (1) DE60143477D1 (enExample)
DK (1) DK1280486T3 (enExample)
ES (1) ES2357699T3 (enExample)
MX (2) MX342305B (enExample)
PT (1) PT1280486E (enExample)
WO (1) WO2001080796A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
DK1280486T3 (da) 2000-04-26 2011-02-14 Watson Pharmaceuticals Inc Minimering af bivirkning forbundet med oxybutinin-terapi
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
ATE356636T1 (de) 2000-08-03 2007-04-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
WO2003053292A1 (en) * 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
JP4354678B2 (ja) * 2002-08-28 2009-10-28 久光製薬株式会社 貼付剤
US7276068B2 (en) 2002-10-04 2007-10-02 Sherwood Services Ag Vessel sealing instrument with electrical cutting mechanism
AU2012216593B2 (en) * 2002-11-01 2014-09-25 Allergan Sales, Llc Compositions and methods for transdermal oxybutynin therapy
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
DE10315878B4 (de) * 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en) * 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
JP5097359B2 (ja) 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10149828B2 (en) 2015-01-09 2018-12-11 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
US11033511B2 (en) 2017-08-01 2021-06-15 Hisamitsu Pharmaceutical Co., Inc. Pharmaceutical patch

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
NL267508A (enExample) * 1960-07-26
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
CA2063576C (en) * 1989-06-07 1994-01-25 Gail S. Bazzano Slow release vehicles for minimizing skin irritancy of topical compositions
US5922342A (en) 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
JP3786684B2 (ja) * 1992-05-13 2006-06-14 アルザ・コーポレーション オキシブチニンの経皮投与
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
NZ274711A (en) 1993-09-29 1996-11-26 Alza Corp Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s)
WO1995024172A1 (en) 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
US5441740A (en) * 1994-05-06 1995-08-15 Longevity Network. Ltd. Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
WO1996011022A1 (en) * 1994-10-05 1996-04-18 Hisamitsu Pharmaceutical Co., Inc. DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-o-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5862555A (en) 1995-04-06 1999-01-26 Furuhashi; Masanobu System and method for manufacturing shoes using a wooden mold
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
ATE235224T1 (de) 1996-02-02 2003-04-15 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5769683A (en) * 1997-02-10 1998-06-23 Park; Young-Ho Attachment for balloon tether
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6479373B2 (en) * 1997-02-20 2002-11-12 Infineon Technologies Ag Method of structuring layers with a polysilicon layer and an overlying metal or metal silicide layer using a three step etching process with fluorine, chlorine, bromine containing gases
PT973499E (pt) 1997-03-31 2003-12-31 Alza Corp Sistema de administracao difusor implantavel
EP0971641A4 (en) * 1997-04-03 2003-08-13 Point Biomedical Corp SYSTEM FOR THE ADMINISTRATION OF AN INTRAVESICAL MEDICINAL PRODUCT
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IL136042A (en) * 1997-11-10 2005-12-18 Cellegy Pharma Inc Alcohol-containing composition for topical application
US5891888A (en) * 1998-01-14 1999-04-06 Strahl; Robert Charles Physical endurance drink
DE29823343U1 (de) * 1998-03-20 1999-07-15 Schwarz Pharma Ag, 40789 Monheim Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
AR018321A1 (es) 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US5986305A (en) * 1998-03-30 1999-11-16 Texas Instruments - Acer Incorporated Semiconductor device with an inverse-T gate lightly-doped drain structure
FR2779438B1 (fr) * 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
DK1280486T3 (da) 2000-04-26 2011-02-14 Watson Pharmaceuticals Inc Minimering af bivirkning forbundet med oxybutinin-terapi
US6682368B2 (en) * 2000-05-31 2004-01-27 Tyco Electronics Corporation Electrical connector assembly utilizing multiple ground planes
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
US6662368B1 (en) * 2000-09-11 2003-12-09 Arris International, Inc. Variable spare circuit group size and quantity having multiple active circuits

Also Published As

Publication number Publication date
US20050048106A1 (en) 2005-03-03
WO2001080796A1 (en) 2001-11-01
CN101305994A (zh) 2008-11-19
JP2017008085A (ja) 2017-01-12
JP6077294B2 (ja) 2017-02-08
US7081250B2 (en) 2006-07-25
US7087241B2 (en) 2006-08-08
EP1992342A1 (en) 2008-11-19
US6743441B2 (en) 2004-06-01
AU5378201A (en) 2001-11-07
EP1280486A1 (en) 2003-02-05
CN101843601A (zh) 2010-09-29
AU2001253782B2 (en) 2006-06-29
ES2357699T3 (es) 2011-04-28
JP2003531157A (ja) 2003-10-21
CN102327253A (zh) 2012-01-25
ATE488233T1 (de) 2010-12-15
US20050048107A1 (en) 2005-03-03
US20040120996A1 (en) 2004-06-24
DE60143477D1 (de) 2010-12-30
EP1280486B1 (en) 2010-11-17
BR0110381A (pt) 2003-12-30
HK1052287A1 (en) 2003-09-11
US20020147236A1 (en) 2002-10-10
MX342305B (es) 2016-09-23
US7081252B2 (en) 2006-07-25
CA2406064A1 (en) 2001-11-01
US20040259954A1 (en) 2004-12-23
EP2322170A1 (en) 2011-05-18
MXPA02010542A (es) 2003-10-14
JP6253734B2 (ja) 2017-12-27
US7081249B2 (en) 2006-07-25
US7081251B2 (en) 2006-07-25
CA2406064C (en) 2011-03-15
JP2013082720A (ja) 2013-05-09
CY1111498T1 (el) 2015-08-05
CN1438861A (zh) 2003-08-27
US20060078613A1 (en) 2006-04-13
EP1280486A4 (en) 2006-03-29
PT1280486E (pt) 2011-02-28

Similar Documents

Publication Publication Date Title
DK1280486T3 (da) Minimering af bivirkning forbundet med oxybutinin-terapi
MY134129A (en) Polymorphs of an epothilone analog
DK1414486T3 (da) Anvendelse af GLP-2 i kombination med et andet terapeutisk middel ved knoglerelaterede sygdomme
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
CY1110547T1 (el) Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
PA8545301A1 (es) Nuevos derivados de quinolina
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
ECSP066759A (es) Combinaciones de productos activos insecticidas a base de thiacloprid y de piretroides
DK1363641T3 (da) Progestagen, der er co-mikroniseret med et overfladeaktivt middel, farmaceutisk præparat, som indeholder det, fremgangsmåder til fremstilling deraf samt anvendelser deraf
ITMI20021897A1 (it) Seggiolone con dondolo per bambini.
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
ATE344234T1 (de) Salicylamid-derivate
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
AU2002238779A1 (en) Seat for cyclist
NO20023517D0 (no) Stol
ATE464808T1 (de) Zusammenklappbare bar
SV2004001441A (es) Compuestos de isocromano ref. x-14205
ITRM20000448A0 (it) Uso di un'associazione di vitamine per il trattamento delle cefalee primarie.
DK0521967T3 (da) Ny anvendelse af bambuterol
侯毅凌 Self-esteem vs. Self-respect The Power Lies in the Difference
SE9904252L (sv) Handtagsförlängare för rullbara vagnar